Rxn Chemicals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 14-12-2024
- Paid Up Capital ₹ 0.10 M
as on 14-12-2024
- Company Age 13 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 34.91%
(FY 2022)
- Profit 118.09%
(FY 2022)
- Ebitda 138.81%
(FY 2022)
- Net Worth 11.78%
(FY 2022)
- Total Assets 14.78%
(FY 2022)
About Rxn Chemicals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Balasaheb Kakade and Ritu Kakade serve as directors at the Company.
- CIN/LLPIN
U24100MH2011PTC220069
- Company No.
220069
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Jul 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Rxn Chemicals Private Limited offer?
Rxn Chemicals Private Limited offers a wide range of products and services, including Cosmetics, Hair & Beauty Products, Cosmetic Raw Material, Respiratory System Drugs, Anti Asthma Drug, Nutraceuticals & Dietary Supplements, Vitamin Tablets & Capsules, Industrial Chemicals & Supplies, Chemical Compound, Cooking Spices and Masala, Edible Salt.
Who are the key members and board of directors at Rxn Chemicals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Balasaheb Kakade  | Managing Director | 22-Jul-2011 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ritu Kakade | Director | 22-Jul-2011 | Current |
Financial Performance of Rxn Chemicals.
Rxn Chemicals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 34.91% increase. The company also saw a substantial improvement in profitability, with a 118.09% increase in profit. The company's net worth Soared by an impressive increase of 11.78%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rxn Chemicals?
In 2018, Rxn Chemicals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Dugen Pharma Private LimitedActive 5 years 10 monthsBalasaheb Kakade and Ritu Kakade are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Rxn Chemicals?
Unlock and access historical data on people associated with Rxn Chemicals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rxn Chemicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rxn Chemicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
